ClinicalTrials.gg
CompletedNCT04709835Updated Oct 26, 2022Results posted

Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19

A Phase 2 interventional study of AT-527 and Placebo in COVID-19, sponsored by Hoffmann-La Roche. Completed at 12 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-26.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 340 studies in COVID-19 with a site in United Kingdom — 17 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · United Kingdom.

Enrollment
116th of 172
104 · median 247
Started
2021
with 82 others
Phase 2
27 of 340
none open now
Registered
189th of 340
by date

Among the 340 studies in COVID-19 with a site in United Kingdom, this one is the 116th largest by enrollment of the 172 interventional ones that give a count, is one of 83 that started in 2021, is one of 27 in phase 2, and was the 189th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

17 of the 340 studies in COVID-19 with a site in United Kingdom are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 340 studies in COVID-19 with a site in United Kingdom, or all of them as a file.
02

Study summary

This randomized study evaluates the antiviral activity, safety, efficacy and pharmacokinetics of AT-527 versus a placebo in participants with mild or moderate coronavirus disease (COVID-19) who are not hospitalized.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive SARS-CoV-2 diagnostic test (RT-PCR or rapid antigen test)at screening
  • Has symptoms consistent with mild or moderate COVID-19, as determined by the investigator, with onset ≤5 days prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Clinical signs indicative of COVID-19 illness requiring hospitalization, defined as any of the following: shortness of breath at rest, respiratory rate ≥30, heart rate ≥125, peripheral capillary oxygen saturation ≤93% on room air
  • Treatment with a therapeutic agent against SARS-CoV-2 including, but not limited to, other direct acting antivirals, convalescent plasma, monoclonal antibodies against SARS CoV-2, or intravenous immunoglobulin within 3 months or less than 5 drug elimination half-lives (whichever is longer) prior to screening
  • Requirement, in the opinion of the investigator, for any of the prohibited medications during the study
  • Use of hydroxychloroquine or amiodarone within 3 months of screening
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 30 days after the final dose of AT-527. Women of must have a negative urine pregnancy test result at screening
  • Abnormal laboratory test results at screening
  • abnormal , as determined by the Investigator, at screening
  • Planned procedure or surgery during the study
  • Known allergy or to study drug or drug product
  • Substance abuse, as determined by the investigator, within 12 months prior to screening
  • Poor peripheral venous access
  • Malabsorption syndrome or other condition that would interfere with enteral absorption
  • Any clinically significant history of epistaxis within the last 3 months and/or history of being hospitalized due to epistaxis of any previous occasion
  • History of anaphylaxis
  • Any uncontrolled serious medical condition or other clinically significant abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive AT-527-matched placebo twice a day (BID) on Days 1-5.

    Drug: Placebo

  • Experimental
    AT-527 550 mg (1x550 mg)

    Participants will receive 550 mg AT-527 (1x550 mg) twice a day (BID) on Days 1-5.

    Drug: AT-527

  • Experimental
    AT-527 1100 mg (4x275 mg)

    Participants will receive 1100 mg AT-527 (4x275 mg) twice a day (BID) on Days 1-5.

    Drug: AT-527

Interventions

  • DrugAT-527

    Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg.

    Also known as: RO7496998

  • DrugPlacebo

    The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA for AT-527 550 mg and Matched Placebo

    SARS-CoV-2 virus RNA was measured by reverse-transcription polymerase chain reaction (RT-PCR) from nasopharyngeal (NP) swabs. The change from baseline was estimated from an ANCOVA model with baseline viral load as a covariate. Reported here is the adjusted mean change from baseline. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Day 3, Day 5, Day 7

  2. Change From Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA for AT-527 1100 mg and Pooled Placebo

    SARS-CoV-2 virus RNA was measured by reverse-transcription polymerase chain reaction (RT-PCR) from NP swabs. The change from baseline was estimated from an ANCOVA model with baseline viral load as a covariate. Reported here is the adjusted mean change from baseline. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Day 3, Day 5, Day 7

Secondary outcomes

  1. Time to Cessation of SARS-CoV-2 Viral Shedding

    Time to cessation of viral shedding was defined as the time between the initiation of any study treatment and the first time when a negative or below the limit of detection RT-PCR test result was obtained. RT-PCR was measured from NP swabs. Median, 25th and 75th percentiles were estimated from the Kaplan-Meier curve.

    Time frame: Up to Day 7

  2. Time to Sustained Non-Detectable SARS-CoV-2 Virus RNA

    Time to sustained non-detectable SARS-CoV-2 virus RNA was defined as the time between the initiation of any study treatment and first time when a negative or below the limit of detection test result by RT-PCR is obtained after which no positive test above or equal to the limit of detection was reported. RT-PCR was measured from NP swabs. Median, 25th and 75th percentiles were estimated from the Kaplan-Meier curve.

    Time frame: Up to Day 7

  3. Percentage of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints

    Reported here is the percentage of participants with a positive virus RNA by RT-PCR test result above or equal to the limit of quantification (LOQ). RT-PCR was measured from NP swabs.

    Time frame: Baseline, Day 3, Day 5, Day 7

  4. Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA

    AUC is the amount of SARS-CoV-2 virus RNA from baseline to the last sample timepoint and was calculated using the trapezoidal method. RT-PCR was measured from NP swabs.

    Time frame: Baseline, Day 3, Day 5, Day 7

  5. Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 Hours)

    COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe).Time to alleviation or improvement is defined as the length of time taken from start of treatment to the point at which all of the following three criteria are met and maintained for a concurrent duration of at least 21.5 hours: "new" symptoms with a score of 0 or 1; "pre- existing and worsened due to COVID-19" symptoms with at least a single category improvement from baseline; "pre-existing and not worsened due to COVID-19" symptoms remaining the same or at least a single category improvement from baseline.

    Time frame: Up to 28 Days

  6. Time to Alleviation or Improvement of COVID-19 Symptoms (43 Hours)

    COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). Time to alleviation or improvement is defined as the length of time taken from start of treatment to the point at which all of the following three criteria are met and maintained for a concurrent duration of at least 43 hours: "new" symptoms with a score of 0 or 1; "pre- existing and worsened due to COVID-19" symptoms with at least a single category improvement from baseline; "pre-existing and not worsened due to COVID-19" symptoms remaining the same or at least a single category improvement from baseline.

    Time frame: Up to 28 Days

  7. Time to Alleviation of COVID-19 Symptoms (21.5 Hours)

    COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). Time to alleviation of COVID-19 symptoms is defined as the length of time taken from start of treatment to the point at which the following criterion is met and maintained for at least 21.5 hours: Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary, regardless of if the symptom is pre-existing or new.

    Time frame: Up to 28 Days

  8. Time to Alleviation of COVID-19 Symptoms (43 Hours)

    COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). Time to alleviation of COVID-19 symptoms is defined as the length of time taken from start of treatment to the point at which the following criterion is met and maintained for at least 43 hours: Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary, regardless of if the symptom is pre-existing or new.

    Time frame: Up to 28 Days

  9. Duration of Fever

    Duration of fever was defined as the time from start of treatment to return to an afebrile state (temperature ≤ 37.5°C) maintained for at least 21.5 hours.

    Time frame: Up to 28 Days

  10. Percentage of Participants With COVID-19 Related Complications

    COVID-19 related complications include death, hospitalization, radiologically confirmed pneumonia, acute respiratory failure, sepsis, coagulopathy, pericarditis, myocarditis, and cardiac failure.

    Time frame: Up to 33 Days

  11. Time to Alleviation of an Individual Symptom

    The COVID-19 Symptom Diary included the following 14 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, diarrhea, sense of smell over the past 7 days and sense of taste over the past 7 days. The severity of items 1-12 was recorded on a 4-point Likert scale (none=0, mild=1, moderate=2, severe=3). Items 13-14 were recorded on a 3-point Likert scale (same as usual=0, less than usual=1, no sense=2). Time to alleviation of an individual symptom was defined as the time taken from the start of treatment to the point at which the following criterion was met and maintained (for each individual symptom) for at least 21.5 hours: score of 0 or 1 for Items 1-12 of the COVID-19 Symptom Diary; score of 0 for Items 13 and 14 of the COVID-19 Symptom Diary.

    Time frame: Up to 28 Days

  12. Percentage of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following: any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition not present at baseline or related to a protocol-mandated intervention.

    Time frame: Up to 33 Days

  13. Plasma Concentrations of AT-511, AT-551, AT-229 and AT-273 for Participants Treated With 550 mg AT-527

    AT-511 is the free base form of AT-527. Its major metabolites are AT-551, AT-229, and AT-273.

    Time frame: Day 1: pre-dose, 1 hour, 3 hours; Day 3: pre-dose; Day 5: pre-dose, 3 hours, 48 hours

  14. Plasma Concentrations of AT-511, AT-551, AT-229 and AT-273 for Participants Treated With 1100 mg AT-527

    AT-511 is the free base form of AT-527. Its major metabolites are AT-551, AT-229, and AT-273.

    Time frame: Day 1: pre-dose, 1 hour, 4 hours; Day 3: pre-dose; Day 5: pre-dose, 1 hour, 4 hours, 48 hours

07

Results

Posted Oct 13, 2022

Participant flow

Participants were enrolled in the study at sites in the United Kingdom, Spain, Greece, Latvia, Ireland and Canada.

Participant flow — Overall Study
MilestonePooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
Started403030
Completed402930
Not completed010
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryChange From Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA for AT-527 550 mg and Matched Placebo

SARS-CoV-2 virus RNA was measured by reverse-transcription polymerase chain reaction (RT-PCR) from nasopharyngeal (NP) swabs. The change from baseline was estimated from an ANCOVA model with baseline viral load as a covariate. Reported here is the adjusted mean change from baseline. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Day 3, Day 5, Day 7
Reported as:
Mean · log10 copies/mL
Change From Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA for AT-527 550 mg and Matched Placebo
log10 copies/mLPlacebo Matched to AT-527 550 mgAT-527 550 mg (1x550 mg)
Day 3-1.16 ± 0.203-1.26 ± 0.206
Day 5-2.42 ± 0.230-2.11 ± 0.226
Day 7-3.13 ± 0.220-3.38 ± 0.220
Statistical analysis
  • Placebo Matched to AT-527 550 mg vs AT-527 550 mg (1x550 mg) · ANCOVA · p = 0.7144 · Difference in adjusted means: -0.11 · 80% CI -0.49 to 0.27A difference in adjusted means of \<0 favors RO7496998 (AT-527).
  • Placebo Matched to AT-527 550 mg vs AT-527 550 mg (1x550 mg) · ANCOVA · p = 0.3373 · Difference in adjusted means: 0.32 · 80% CI -0.11 to 0.74A difference in adjusted means of \<0 favors RO7496998 (AT-527).
  • Placebo Matched to AT-527 550 mg vs AT-527 550 mg (1x550 mg) · ANCOVA · p = 0.4260 · Difference in adjusted means: -0.25 · 80% CI -0.66 to 0.16A difference in adjusted means of \<0 favors RO7496998 (AT-527).
SecondaryTime to Cessation of SARS-CoV-2 Viral Shedding

Time to cessation of viral shedding was defined as the time between the initiation of any study treatment and the first time when a negative or below the limit of detection RT-PCR test result was obtained. RT-PCR was measured from NP swabs. Median, 25th and 75th percentiles were estimated from the Kaplan-Meier curve.

Time frame:
Up to Day 7
Reported as:
Median · hours
Time to Cessation of SARS-CoV-2 Viral Shedding
hoursPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
Time to Cessation of SARS-CoV-2 Viral SheddingNA (144.2 to NA)NA (143.8 to NA)NA (141.1 to NA)
Statistical analysis
  • Pooled Placebo vs AT-527 550 mg (1x550 mg) · Hazard ratio (hr): 0.96 · 80% CI 0.53 to 1.74Hazard ratio (80% CI) was estimated with a Cox proportional hazards model (unadjusted).
  • Pooled Placebo vs AT-527 1100 mg (4x275 mg) · Hazard ratio (hr): 1.33 · 80% CI 0.76 to 2.32Hazard ratio (80% CI) was estimated with a Cox proportional hazards model (unadjusted).
SecondaryTime to Sustained Non-Detectable SARS-CoV-2 Virus RNA

Time to sustained non-detectable SARS-CoV-2 virus RNA was defined as the time between the initiation of any study treatment and first time when a negative or below the limit of detection test result by RT-PCR is obtained after which no positive test above or equal to the limit of detection was reported. RT-PCR was measured from NP swabs. Median, 25th and 75th percentiles were estimated from the Kaplan-Meier curve.

Time frame:
Up to Day 7
Reported as:
Median · hours
Time to Sustained Non-Detectable SARS-CoV-2 Virus RNA
hoursPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
Time to Sustained Non-Detectable SARS-CoV-2 Virus RNANA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pooled Placebo vs AT-527 550 mg (1x550 mg) · Hazard ratio (hr): 0.86 · 80% CI 0.44 to 1.70Hazard ratio (80% CI) was estimated with a Cox proportional hazards model (unadjusted).
  • Pooled Placebo vs AT-527 1100 mg (4x275 mg) · Hazard ratio (hr): 1.06 · 80% CI 0.56 to 2.03Hazard ratio (80% CI) was estimated with a Cox proportional hazards model (unadjusted).
SecondaryPercentage of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints

Reported here is the percentage of participants with a positive virus RNA by RT-PCR test result above or equal to the limit of quantification (LOQ). RT-PCR was measured from NP swabs.

Time frame:
Baseline, Day 3, Day 5, Day 7
Reported as:
Number · percentage of participants
Percentage of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints
percentage of participantsPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
Baseline10010096.7
Day 395.010093.1
Day 584.290.083.3
Day 776.979.376.7
Statistical analysis
  • Pooled Placebo vs AT-527 550 mg (1x550 mg) · Difference in percentage of positivity: 5.00 · 80% CI -0.16 to 10.16Confidence interval estimated with the Farrington-Manning method.
  • Pooled Placebo vs AT-527 1100 mg (4x275 mg) · Difference in percentage of positivity: -1.90 · 80% CI -9.20 to 5.41Confidence interval estimated with the Farrington-Manning method.
  • Pooled Placebo vs AT-527 550 mg (1x550 mg) · Difference in percentage of positivity: 5.79 · 80% CI -4.82 to 16.40Confidence interval estimated with the Farrington-Manning method.
  • Pooled Placebo vs AT-527 1100 mg (4x275 mg) · Difference in percentage of positivity: -0.88 · 80% CI -12.40 to 10.65Confidence interval estimated with the Farrington-Manning method.
  • Pooled Placebo vs AT-527 550 mg (1x550 mg) · Difference in percentage of positivity: 2.39 · 80% CI -10.64 to 15.42Confidence interval estimated with the Farrington-Manning method.
  • Pooled Placebo vs AT-527 1100 mg (4x275 mg) · Difference in percentage of positivity: -0.26 · 80% CI -13.39 to 12.88Confidence interval estimated with the Farrington-Manning method.
SecondaryArea Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA

AUC is the amount of SARS-CoV-2 virus RNA from baseline to the last sample timepoint and was calculated using the trapezoidal method. RT-PCR was measured from NP swabs.

Time frame:
Baseline, Day 3, Day 5, Day 7
Reported as:
Mean · log10 copies/mL*hour
Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA
log10 copies/mL*hourPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA651.56 ± 189.10733.70 ± 146.63618.62 ± 194.88
SecondaryTime to Alleviation or Improvement of COVID-19 Symptoms (21.5 Hours)

COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe).Time to alleviation or improvement is defined as the length of time taken from start of treatment to the point at which all of the following three criteria are met and maintained for a concurrent duration of at least 21.5 hours: "new" symptoms with a score of 0 or 1; "pre- existing and worsened due to COVID-19" symptoms with at least a single category improvement from baseline; "pre-existing and not worsened due to COVID-19" symptoms remaining the same or at least a single category improvement from baseline.

Time frame:
Up to 28 Days
Reported as:
Median · hours
Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 Hours)
hoursPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 Hours)43.4 (9.3 to 104.7)57.2 (9.0 to 115.8)56.4 (2.5 to 96.4)
SecondaryTime to Alleviation or Improvement of COVID-19 Symptoms (43 Hours)

COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). Time to alleviation or improvement is defined as the length of time taken from start of treatment to the point at which all of the following three criteria are met and maintained for a concurrent duration of at least 43 hours: "new" symptoms with a score of 0 or 1; "pre- existing and worsened due to COVID-19" symptoms with at least a single category improvement from baseline; "pre-existing and not worsened due to COVID-19" symptoms remaining the same or at least a single category improvement from baseline.

Time frame:
Up to 28 Days
Reported as:
Median · hours
Time to Alleviation or Improvement of COVID-19 Symptoms (43 Hours)
hoursPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
Time to Alleviation or Improvement of COVID-19 Symptoms (43 Hours)43.4 (9.3 to 104.7)57.2 (9.0 to 141.2)58.1 (2.5 to 118.2)
SecondaryTime to Alleviation of COVID-19 Symptoms (21.5 Hours)

COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). Time to alleviation of COVID-19 symptoms is defined as the length of time taken from start of treatment to the point at which the following criterion is met and maintained for at least 21.5 hours: Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary, regardless of if the symptom is pre-existing or new.

Time frame:
Up to 28 Days
Reported as:
Median · hours
Time to Alleviation of COVID-19 Symptoms (21.5 Hours)
hoursPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
Time to Alleviation of COVID-19 Symptoms (21.5 Hours)43.4 (9.3 to 104.7)57.2 (9.0 to 115.8)56.4 (8.2 to 96.4)
SecondaryTime to Alleviation of COVID-19 Symptoms (43 Hours)

COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). Time to alleviation of COVID-19 symptoms is defined as the length of time taken from start of treatment to the point at which the following criterion is met and maintained for at least 43 hours: Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary, regardless of if the symptom is pre-existing or new.

Time frame:
Up to 28 Days
Reported as:
Median · hours
Time to Alleviation of COVID-19 Symptoms (43 Hours)
hoursPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
Time to Alleviation of COVID-19 Symptoms (43 Hours)43.4 (9.3 to 104.7)57.2 (9.0 to 141.2)58.1 (8.2 to 118.2)
SecondaryDuration of Fever

Duration of fever was defined as the time from start of treatment to return to an afebrile state (temperature ≤ 37.5°C) maintained for at least 21.5 hours.

Time frame:
Up to 28 Days
Reported as:
Median · hours
Duration of Fever
hoursPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
Duration of Fever10.6 (9.6 to 11.7)——
SecondaryPercentage of Participants With COVID-19 Related Complications

COVID-19 related complications include death, hospitalization, radiologically confirmed pneumonia, acute respiratory failure, sepsis, coagulopathy, pericarditis, myocarditis, and cardiac failure.

Time frame:
Up to 33 Days
Reported as:
Number · percentage of participants
Percentage of Participants With COVID-19 Related Complications
percentage of participantsPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
Percentage of Participants With COVID-19 Related Complications03.33.3
SecondaryTime to Alleviation of an Individual Symptom

The COVID-19 Symptom Diary included the following 14 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, diarrhea, sense of smell over the past 7 days and sense of taste over the past 7 days. The severity of items 1-12 was recorded on a 4-point Likert scale (none=0, mild=1, moderate=2, severe=3). Items 13-14 were recorded on a 3-point Likert scale (same as usual=0, less than usual=1, no sense=2). Time to alleviation of an individual symptom was defined as the time taken from the start of treatment to the point at which the following criterion was met and maintained (for each individual symptom) for at least 21.5 hours: score of 0 or 1 for Items 1-12 of the COVID-19 Symptom Diary; score of 0 for Items 13 and 14 of the COVID-19 Symptom Diary.

Time frame:
Up to 28 Days
Reported as:
Median · hours
Time to Alleviation of an Individual Symptom
hoursPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
Nasal Congestion/Runny Nose27.6 (11.3 to 59.9)34.2 (15.8 to 82.4)32.7 (10.0 to 57.7)
Sore Throat20.5 (14.1 to 22.7)24.1 (9.8 to 45.0)111.7 (22.1 to 201.4)
Cough22.6 (11.8 to 129.3)90.7 (23.7 to 140.4)33.9 (20.5 to 119.2)
Shortness of Breath23.9 (11.5 to NA)68.9 (68.5 to 69.2)11.6 (11.6 to 11.6)
Aches and Pains33.1 (11.8 to 60.4)22.3 (16.3 to 62.2)94.4 (48.1 to 177.7)
Fatigue47.8 (22.6 to 178.1)44.4 (10.5 to 94.5)70.6 (22.6 to 106.0)
Headache32.0 (10.1 to 95.8)11.7 (9.8 to 93.6)34.4 (21.8 to 105.4)
Chills/Sweats11.8 (9.8 to 24.1)12.0 (9.0 to 35.8)25.0 (17.1 to 41.4)
Feeling Hot or Feverish26.5 (11.8 to 35.7)48.0 (24.0 to 72.0)40.3 (15.9 to 63.4)
NauseaNA (21.1 to NA)——
VomitingNA (11.0 to NA)——
DiarrheaNA (NA to NA)—9.8 (9.8 to 9.8)
Sense of Smell261.5 (164.9 to NA)290.2 (130.7 to NA)213.1 (129.7 to 513.7)
Sense of Taste221.1 (165.3 to 297.6)214.1 (94.1 to NA)178.5 (105.5 to 391.2)
SecondaryPercentage of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following: any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition not present at baseline or related to a protocol-mandated intervention.

Time frame:
Up to 33 Days
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
Percentage of Participants With Adverse Events (AEs)27.520.033.3
SecondaryPlasma Concentrations of AT-511, AT-551, AT-229 and AT-273 for Participants Treated With 550 mg AT-527

AT-511 is the free base form of AT-527. Its major metabolites are AT-551, AT-229, and AT-273.

Time frame:
Day 1: pre-dose, 1 hour, 3 hours; Day 3: pre-dose; Day 5: pre-dose, 3 hours, 48 hours
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentrations of AT-511, AT-551, AT-229 and AT-273 for Participants Treated With 550 mg AT-527
nanograms per milliliter (ng/mL)AT-527 550 mg (1x550 mg)
AT-511: Day 1, pre-dose1.3 ± 4.5
AT-511: Day 1, 1 hour1950.5 ± 2365.0
AT-511: Day 1, 3 hours441.4 ± 645.8
AT-511: Day 3, pre-dose254.2 ± 943.1
AT-511: Day 5, pre-dose5.6 ± 21.9
AT-511: Day 5, 3 hours415.7 ± 445.5
AT-511: Day 5, 48 hours0.5 ± 0.0
AT-551: Day 1, pre-dose0.5 ± 0.0
AT-551: Day 1, 1 hour347.5 ± 334.1
AT-551: Day 1, 3 hours375.8 ± 303.9
AT-551: Day 3, pre-dose56.9 ± 100.1
AT-551: Day 5, pre-dose26.6 ± 22.7
AT-551: Day 5, 3 hours323.8 ± 168.3
AT-551: Day 5, 48 hours1.7 ± 1.4
AT-229: Day 1, pre-dose0.5 ± 0.0
AT-229: Day 1, 1 hour268.5 ± 318.5
AT-229: Day 1, 3 hours427.4 ± 275.8
AT-229: Day 3, pre-dose290.3 ± 152.3
AT-229: Day 5, pre-dose295.4 ± 145.0
AT-229: Day 5, 3 hours773.9 ± 340.8
AT-229: Day 5, 48 hours89.2 ± 87.8
AT-273: Day 1, pre-dose0.5 ± 0.0
AT-273: Day 1, 1 hour26.5 ± 29.0
AT-273: Day 1, 3 hours132.2 ± 66.7
AT-273: Day 3, pre-dose135.9 ± 47.6
AT-273: Day 5, pre-dose138.1 ± 53.0
AT-273: Day 5, 3 hours236.9 ± 79.9
AT-273: Day 5, 48 hours40.9 ± 22.7
SecondaryPlasma Concentrations of AT-511, AT-551, AT-229 and AT-273 for Participants Treated With 1100 mg AT-527

AT-511 is the free base form of AT-527. Its major metabolites are AT-551, AT-229, and AT-273.

Time frame:
Day 1: pre-dose, 1 hour, 4 hours; Day 3: pre-dose; Day 5: pre-dose, 1 hour, 4 hours, 48 hours
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentrations of AT-511, AT-551, AT-229 and AT-273 for Participants Treated With 1100 mg AT-527
nanograms per milliliter (ng/mL)AT-527 1100 mg (4x275 mg)
AT-511: Day 1, pre-dose0.5 ± 0.0
AT-511: Day 1, 1 hour3575.0 ± 2883.6
AT-511: Day 1, 4 hours852.4 ± 1513.2
AT-511: Day 3, pre-dose9.6 ± 15.9
AT-511: Day 5, pre-dose316.7 ± 1544.7
AT-511: Day 5, 1 hour3568.9 ± 3352.1
AT-511: Day 5, 4 hours1323.3 ± 2883.5
AT-511: Day 5, 48 hours0.6 ± 0.6
AT-551: Day 1, pre-dose0.5 ± 0.0
AT-551: Day 1, 1 hour592.2 ± 576.9
AT-551: Day 1, 4 hours640.4 ± 446.3
AT-551: Day 3, pre-dose84.0 ± 72.1
AT-551: Day 5, pre-dose71.3 ± 61.6
AT-551: Day 5, 1 hour302.8 ± 222.1
AT-551: Day 5, 4 hours342.1 ± 254.9
AT-551: Day 5, 48 hours4.4 ± 4.8
AT-229: Day 1, pre-dose0.5 ± 0.0
AT-229: Day 1, 1 hour371.9 ± 460.3
AT-229: Day 1, 4 hours865.4 ± 494.2
AT-229: Day 3, pre-dose682.8 ± 351.7
AT-229: Day 5, pre-dose797.8 ± 459.9
AT-229: Day 5, 1 hour990.9 ± 505.3
AT-229: Day 5, 4 hours1357.2 ± 825.3
AT-229: Day 5, 48 hours279.4 ± 285.3
AT-273: Day 1, pre-dose0.5 ± 0.0
AT-273: Day 1, 1 hour35.7 ± 47.4
AT-273: Day 1, 4 hours231.8 ± 111.4
AT-273: Day 3, pre-dose245.6 ± 122.8
AT-273: Day 5, pre-dose263.6 ± 107.3
AT-273: Day 5, 1 hour252.1 ± 97.4
AT-273: Day 5, 4 hours310.6 ± 107.5
AT-273: Day 5, 48 hours84.4 ± 45.5
PrimaryChange From Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA for AT-527 1100 mg and Pooled Placebo

SARS-CoV-2 virus RNA was measured by reverse-transcription polymerase chain reaction (RT-PCR) from NP swabs. The change from baseline was estimated from an ANCOVA model with baseline viral load as a covariate. Reported here is the adjusted mean change from baseline. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Day 3, Day 5, Day 7
Reported as:
Mean · log10 copies/mL
Change From Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA for AT-527 1100 mg and Pooled Placebo
log10 copies/mLPooled PlaceboAT-527 1100 mg (4x275 mg)
Day 3-1.08 ± 0.190-1.18 ± 0.223
Day 5-2.21 ± 0.205-2.31 ± 0.231
Day 7-2.70 ± 0.207-2.78 ± 0.236
Statistical analysis
  • Pooled Placebo vs AT-527 1100 mg (4x275 mg) · ANCOVA · p = 0.7351 · Difference in adjusted means: -0.10 · 80% CI -0.48 to 0.28A difference in adjusted means of \<0 favors RO7496998 (AT-527).
  • Pooled Placebo vs AT-527 1100 mg (4x275 mg) · ANCOVA · p = 0.7524 · Difference in adjusted means: -0.10 · 80% CI -0.50 to 0.30A difference in adjusted means of \<0 favors RO7496998 (AT-527).
  • Pooled Placebo vs AT-527 1100 mg (4x275 mg) · ANCOVA · p = 0.8083 · Difference in adjusted means: -0.08 · 80% CI -0.48 to 0.33A difference in adjusted means of \<0 favors RO7496998 (AT-527).

Adverse events

Collected over Up to 33 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pooled Placebo0/40 (0%)1/40 (2.5%)1/40 (2.5%)
AT-527 550 mg (1x550 mg)0/30 (0%)1/30 (3.3%)1/30 (3.3%)
AT-527 1100 mg (4x275 mg)0/30 (0%)1/30 (3.3%)5/30 (16.7%)
Most frequent serious events
Most frequent serious events
EventPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
COVID-19 pneumoniaInfections and infestations0/401/301/30
Atrial flutterCardiac disorders1/400/300/30
Most frequent other events
Most frequent other events
EventPooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)
VomitingGastrointestinal disorders1/400/305/30
NauseaGastrointestinal disorders1/401/303/30

Baseline characteristics

The modified ITT infected (mITTi) population was defined as all participants randomized in the study who received any amount of study drug and had at least one positive SARS-CoV-2 RT-PCR test result above or equal to the limit of quantification (LOQ) during the study, with participants grouped according to the treatment assignment at randomization.

Age, Continuous
Age, Continuous(years)Pooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)Total
Mean36.8 ± 13.232.7 ± 10.940.3 ± 15.636.6 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)Pooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)Total
Female22151754
Male18151346
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)Total
Hispanic or Latino3418
Not Hispanic or Latino36262991
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)Total
American Indian or Alaska Native0101
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American2013
White38292895
More than one race0000
Unknown or Not Reported0000
Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA at Baseline
Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA at Baseline(log10 copies/mL)Pooled PlaceboAT-527 550 mg (1x550 mg)AT-527 1100 mg (4x275 mg)Total
Mean6.24 ± 1.406.98 ± 1.105.94 ± 1.466.37 ± 1.39
08

Study locations

12 sites
  • Hamilton Medical Research Group
    Hamilton, Ontario L8M 1K7, Canada
  • National and Kapodistrian University of Athens
    Athens, 115 28, Greece
  • General State Hospital of Nikaia St Panteleimon
    Nikaia Attikis, 184 54, Greece
  • Connolly Hospital
    Dublin, 15, Ireland
  • Outpatient Clinic Adoria
    Rīga, LV-1011, Latvia
  • The Family Physician's Practice of Dr. Maija Kozlovska
    Salaspils, LV-2121, Latvia
  • Hospital Universitario La Paz
    Madrid, 280146, Spain
  • Hospital Universitario Infanta Leonor
    Madrid, 28031, Spain
  • Chapel Street Medical Centre
    Ashton-under-Lyne, OL6 6EW, United Kingdom
  • Tower Family Healthcare - Moorgate Primary Care Ce
    Bury, BL9 0NJ, United Kingdom
  • CPS Research
    Glasgow, G20 0XA, United Kingdom
  • Chelsea and Westminster NHS Trust
    London, SW3 6JJ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Sep 2021, 7 months.

Results were first posted in Oct 2022, 1 year after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 7 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2021
First posted
Jan 14, 2021
StartActual
Feb 3, 2021
Primary completionActual
Sep 17, 2021
CompletionActual
Oct 13, 2021
Results first posted
Oct 13, 2022
Last update
Oct 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04709835
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 14, 2021
Start date
Feb 3, 2021
Primary completion
Sep 17, 2021
Completion
Oct 13, 2021
Results posted
Oct 13, 2022
Last update
Oct 26, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bemnifosbuvir

Start the discussion